webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More
  1. Home
  2. Products
  3. Antibody-Drug Conjugates (ADCs)
  4. Sacituzumab govitecan

Sacituzumab govitecan

  CAS No.: 1491917-83-9   Cat No.: BADC-01603 4.5  

Sacituzumab govitecan is an antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer.

Sacituzumab govitecan

Structure of 1491917-83-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Antibody-Drug Conjugates (ADCs)
Shipping
Store at 4°C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
IMMU-132; IMMU 132; IMMU132
Appearance
Solid
Storage
Store at 4°C

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Manufacturing Services ADC cGMP Manufacturing ADC Fill/Finish ADC Purification ADC Formulation Development Antibody–Drug Conjugate Solutions ADC Early Discovery ADC Process Development ADC Preclinical Studies

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Current Technical Development Trends in Antibody-Drug Conjugate (ADC) Drugs The Development History of ADC Drugs What are Antibody Drug Conjugates? New FDA-Approved ADC: Disitamab Vedotin for Bladder Cancer New ADC Drug for Lymphoma: Loncastuximab Tesirine Overview of Antibody-Drug Conjugate (ADC) Production Technologies ADC Drugs: Unlocking New Frontiers in Tumor Treatment How to Design A Good ADC Drug? Tivdak: FDA's First Approved Tissue Factor-Targeted Antibody-Drug Conjugate How Endocytosis Influences the Receptor Targeting Mechanism of ADC Drugs?

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC Cytotoxin with Linker

ADC Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

ADC Linker

Precise Conjugation For Success

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: MA-PEG4-vc-PAB-DMEA-duocarmycin DM | Sacituzumab govitecan | N-(2-(3,4-dimethylphenoxy)ethyl)-4-formylbenzamide | 2,5-Dioxopyrrolidin-1-Yl 3-(2,4-Di-Tert-Pentylphenoxy)propanoate | Deruxtecan | Pladienolide B | 6-Azidohexanoic acid NHS ester | PNU-159682 | 2,5-dioxopyrrolidin-1-yl 7,10,13-trioxa-4-azahexadec-1-yn-16-oate | Doxorubicin | Daunorubicin
Send Inquiry
Verification code
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout